- Home
- KMI vs CADL Comparison
KMI vs CADL Comparison
Compare KMI & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMI
- CADL
- Stock Information
- Founded
- KMI 1936
- CADL 1999
- Country
- KMI United States
- CADL United States
- Employees
- KMI N/A
- CADL N/A
- Industry
- KMI Natural Gas Distribution
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- KMI Utilities
- CADL Health Care
- Exchange
- KMI Nasdaq
- CADL Nasdaq
- Market Cap
- KMI 58.3B
- CADL 339.8M
- IPO Year
- KMI 2011
- CADL 2021
- Fundamental
- Price
- KMI $26.08
- CADL $5.22
- Analyst Decision
- KMI Buy
- CADL Strong Buy
- Analyst Count
- KMI 13
- CADL 7
- Target Price
- KMI $31.23
- CADL $19.57
- AVG Volume (30 Days)
- KMI 15.0M
- CADL 846.0K
- Earning Date
- KMI 10-22-2025
- CADL 11-14-2025
- Dividend Yield
- KMI 4.49%
- CADL N/A
- EPS Growth
- KMI 7.28
- CADL N/A
- EPS
- KMI 1.22
- CADL N/A
- Revenue
- KMI $16,416,000,000.00
- CADL N/A
- Revenue This Year
- KMI $11.56
- CADL N/A
- Revenue Next Year
- KMI $5.11
- CADL N/A
- P/E Ratio
- KMI $21.37
- CADL N/A
- Revenue Growth
- KMI 8.35
- CADL N/A
- 52 Week Low
- KMI $23.94
- CADL $3.79
- 52 Week High
- KMI $31.48
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- KMI 37.08
- CADL 44.00
- Support Level
- KMI $25.73
- CADL $5.35
- Resistance Level
- KMI $26.40
- CADL $5.80
- Average True Range (ATR)
- KMI 0.58
- CADL 0.34
- MACD
- KMI -0.12
- CADL -0.04
- Stochastic Oscillator
- KMI 19.01
- CADL 9.49
About KMI Kinder Morgan Inc.
Kinder Morgan operates natural gas, crude oil, and refined products pipelines connecting producing regions to demand centers. It is principally involved in the gathering, storage, and transmission of natural gas across the continental United States. It also operates distribution centers for refined products along with the largest fleet of Jones Act-compliant tankers.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.